TY - JOUR T1 - Optimal Stimulation Sites and Networks for Deep Brain Stimulation of the Fornix in Alzheimer’s Disease JF - medRxiv DO - 10.1101/2022.09.08.22279028 SP - 2022.09.08.22279028 AU - Ana Sofía Ríos AU - Simón Oxenford AU - Clemens Neudorfer AU - Konstantin Butenko AU - Ningfei Li AU - Nanditha Rajamani AU - Alexandre Boutet AU - Gavin J.B. Elias AU - Jurgen Germann AU - Aaron Loh AU - Wissam Deeb AU - Fuyixue Wang AU - Kawin Setsompop AU - Bryan Salvato AU - Leonardo Almeida AU - Kelly D. Foote AU - Robert Amaral AU - Paul B. Rosenberg AU - David F. Tang-Wai AU - David A. Wolk AU - Anna D. Burke AU - Stephen Salloway AU - Marwan N. Sabbagh AU - M. Mallar Chakravarty AU - Gwenn S. Smith AU - Constantine G. Lyketsos AU - Michael S. Okun AU - William S. Anderson AU - Zoltan Mari AU - Francisco A. Ponce AU - Andres M. Lozano AU - Andreas Horn Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/09/09/2022.09.08.22279028.abstract N2 - Deep brain stimulation (DBS) to the fornix is an investigational treatment option for patients with mild Alzheimer’s Disease. Outcomes from randomized clinical trials have shown that cognitive function improved in some patients but deteriorated in others. One reason could be variance in electrode placement leading to differential engagement of neural circuits. To investigate this, we analyzed a multi-center cohort of 46 patients with DBS to the fornix. Using normative structural and functional connectivity data, we demonstrate that stimulation of the circuit of Papez and stria terminalis robustly associated with cognitive improvement (R = 0.45, p = 0.031). On a local level, the optimal stimulation site resided at the direct interface between these structures (R = 0.33, p = 0.016). Finally, modulating specific distributed brain networks related to memory accounted for optimal outcomes (R = 0.38, p = 0.006). Findings were robust to multiple cross-validation designs and may now define an optimal network target which could subsequently guide refinement of DBS surgery and programming.Competing Interest StatementC.N. was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG NE 2276/1-1). K.F. received grants and personal fees from Medtronic and Boston Scientific, grants from Abbott/St. Jude, and Functional Neuromodulation outside the submitted work. D.W. received grants from Functional Neuromodulation during conduct of this study, grants and personal fees from Avid/Lily, and Merck, personal fees from Jannsen, GE Healthcare, Biogen and Neuronix outside the submitted work. S.S. receives personal fees from Elsai, Lilly, Roche Novartis and Biogen outside the submitted work. M.S. received personal fees from Allergan, Biogen, Roche-Genentech, Cortexyme, Bracket, Sanofi, and other type of support from Brain Health Inc and uMethod Health outside of the submitted work. C.L. received grants from Functional Neuromodulation Inc. during conduct of this study, from Avanir and Eli Lily and NFL Benefits Office outside of the submitted work. M.O. received grants from NIH, Tourette Association of America Grant, Parkinson’s Alliance, Smallwood Foundation, and personal fees from Parkinson’s Foundation Medical Director, Books4Patients, American Academy of Neurology, Peerview, WebMD/Medscape, Mededicus, Movement Disorders Society, Taylor and Francis, Demos, Robert Rose and non-financial support from Medtronic outside of the submitted work. A.L. received grants from Medtronic and Functional Neuromodulation during conduct of this study, personal fees from Medtronic, St. Jude, Boston Scientific, and Functional Neuromodulation outside of submitted work. A.L. disclosed having a patent “US Patent 8,346,365. Lozano AM. Cognitive function within a human brain. 2013” licensed to Functional Neuromodulation. A.H. was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, 424778381 - TRR 295), Deutsches Zentrum fuer Luftund Raumfahrt (DynaSti grant within the EU Joint Programme Neurodegenerative Disease Research, JPND), the National Institutes of Health (2R01 MH113929) as well as the New Venture Fund (FFOR Seed Grant). ADvance was supported by the National Institute on Aging (R01AG042165) and Functional Neuromodulation Ltd., the sponsor of the study. Other co-authors report no conflicts of interest.Funding StatementC.N. was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG NE 2276/1-1). K.F. received grants and personal fees from Medtronic and Boston Scientific, grants from Abbott/St. Jude, and Functional Neuromodulation outside the submitted work. D.W. received grants from Functional Neuromodulation during conduct of this study, grants and personal fees from Avid/Lily, and Merck, personal fees from Jannsen, GE Healthcare, Biogen and Neuronix outside the submitted work. S.S. receives personal fees from Elsai, Lilly, Roche Novartis and Biogen outside the submitted work. M.S. received personal fees from Allergan, Biogen, Roche-Genentech, Cortexyme, Bracket, Sanofi, and other type of support from Brain Health Inc and uMethod Health outside of the submitted work. C.L. received grants from Functional Neuromodulation Inc. during conduct of this study, from Avanir and Eli Lily and NFL Benefits Office outside of the submitted work. M.O. received grants from NIH, Tourette Association of America Grant, Parkinson’s Alliance, Smallwood Foundation, and personal fees from Parkinson’s Foundation Medical Director, Books4Patients, American Academy of Neurology, Peerview, WebMD/Medscape, Mededicus, Movement Disorders Society, Taylor and Francis, Demos, Robert Rose and non-financial support from Medtronic outside of the submitted work. A.L. received grants from Medtronic and Functional Neuromodulation during conduct of this study, personal fees from Medtronic, St. Jude, Boston Scientific, and Functional Neuromodulation outside of submitted work. A.L. disclosed having a patent “US Patent 8,346,365. Lozano AM. Cognitive function within a human brain. 2013” licensed to Functional Neuromodulation. A.H. was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, 424778381 - TRR 295), Deutsches Zentrum fuer Luftund Raumfahrt (DynaSti grant within the EU Joint Programme Neurodegenerative Disease Research, JPND), the National Institutes of Health (2R01 MH113929) as well as the New Venture Fund (FFOR Seed Grant). ADvance was supported by the National Institute on Aging (R01AG042165) and Functional Neuromodulation Ltd., the sponsor of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics oversight body: Ethikkommision - Charité - Universitaetsmedizin Berlin Study approved under application number: EA2/186/18I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized derivatives of stimulation data used for the described analyses are openly available on OSF (https://osf.io/bckuf). The resulting tract atlas, sweet spot and fMRI network pattern are openly available within Lead-DBS software (www.lead-dbs.org). ER -